Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Gold Fields Limited — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Gold Fields Limited trades at $36.68 (market cap $32.51B). The key difference: Gold Fields Limited is far larger — about 11.4× Dyne Therapeutics Inc. Common Stock's market cap, and Gold Fields Limited pays a 5.92% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Gold Fields Limited for 50 Days on average.
| DYN | GFI | |
|---|---|---|
Market Cap | $2.86B | $32.51B |
Volume | 3,341,579 | 3,490,155 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $61.52 |
52-Week Low | $14.60 | $31.25 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.18B | $33.11B |
Dividend Yield | — | 5.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Gold Fields (GFI) trades at $35.55, down 3.29% amid market reaction to its rejected $27 billion bid for Northern Star. Despite recent earnings misses, the company shows strong fundamentals with a low P/E of 7.4, robust net income margin of 38.66%, and record 2025 revenue of $8.75 billion. Technical indicators are bearish, with the stock near key support at $36. Analyst consensus remains positive with a $52.75 price target, though sentiment is cautious due to acquisition uncertainty.
The outlook for GFI is mixed; its undervalued metrics and high profitability support upside potential, but near-term volatility from the failed acquisition and bearish technicals pose risks. Investors should weigh the company's strong cash flow generation and growth prospects against execution risks and gold price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
